Navigation Links
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
Date:10/15/2007

Investigational Extended-Release Formulation Reduced Seizures in Patients

Who Were Inadequately Controlled

RESEARCH TRIANGLE PARK, N.C., Oct. 15 /PRNewswire-FirstCall/ -- New recently published data show that Lamictal(R)XR(TM) (lamotrigine) Extended- Release Tablets significantly reduced the frequency of partial seizures in inadequately controlled patients with epilepsy.

Lamictal XR is an extended-release formulation of Lamictal(R) (lamotrigine) currently in development as adjunctive therapy for patients with partial epilepsy with or without secondary generalization. Partial seizures, which are the most common form of epilepsy, involve a restricted area of the brain. Secondarily generalized seizures start out affecting only one side of the brain and evolve to affect both sides.

Results from this study, published in the October 16, 2007 edition of Neurology demonstrated that Lamictal XR reduced partial seizures by 46 percent over the entire 19-week treatment period compared to 24 percent with placebo. All patients enrolled in the study were inadequately controlled on one or two antiepileptic drugs. The study also showed that 42 percent of patients treated with Lamictal XR achieved at least a 50 percent reduction in seizure frequency compared to 24 percent of patients receiving placebo, a reduction that was reached by some patients as early as Day 18 of the study and was sustained over the entire 19-week treatment period.

"Many patients require multiple doses of one or more medications to control their epilepsy, which makes taking their medicines correctly and at the right times even more challenging," said Dean Naritoku, M.D., Professor of Neurology and Pharmacology, Southern Illinois University, Springfield, IL. "These data are important as they show investigational Lamictal XR taken once- daily significantly reduced seizure frequency among previously uncontrolled patients.

About This Study

This study
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...N, Mass., Nov. 6 DUSA Ph...ermatology company that is developing and marketin...ther products focused on patients with common skin...nd Chief Executive Officer, will present a corpora...ummit 2009 on Tuesday, November 10, 2009 at 10:00 ...
(Date:11/6/2009)...Calif., Nov. 6 Kaiser Foundation H...P/H), and their subsidiaries reported today a comb...the quarter ended September 30, 2009, compared to ...perating income in the third quarter was $336 mill... of last year. Net non-operating income was $233 m...
(Date:11/6/2009)...Nov. 6 Caraco Pharmaceut...nched ketorolac tromethamine ophthalmic solution, ...nd Drug Administration (FDA) for Sun Pharma,s Abbr...ular® ophthalmic solution on the first day fo...lac is therapeutically equivalent to Acular® ...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 1Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 2Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 3Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 4Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 1Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 2Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 3Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 1Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 2Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 3Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 5
...nc., a,biopharmaceutical company engaged in the di... treatment of immune-mediated diseases, announced ...modified version of TRX1,MTRX1011A, an anti-CD4 mo...hat has begun enrolling patients. The clinical tri...th single and multiple doses of MTRX1011A.,Under t...
...ffectiveness of Autologous Therapy, DUSSELDORF, G...entative study of knee osteoarthritis, published i...itis and Cartilage", confirm,the safety and effect...matory proteins obtained from the patient,s own bl...rchers at Heinrich Heine University in Dusseldorf ...
Other Medicine Technology:Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2
(Date:11/9/2009)...device control capabilities will enable system cen...nhance their data security policy enforcement. , .... 9, 2009 -- Lumension, a global leader in endpoin...eral availability of Lumension® Device Contro...ers to protect corporate data while reducing opera...
(Date:11/9/2009)...rporation announces that their design, production ... Minneapolis, MN (Vocus) November 9, 2... manufacturer of miniature high-rel connectors, an...ms have been certified to the ISO 9001:2000 (w/des...stem Standard., , ,The company,s entire quality sy...
(Date:11/9/2009)... under increasing pressure to play only one sport ... System study of 519 junior tennis players has fou...injury. Researchers who analyzed 3,366 matches in ...n found that players who specialized in only tenni...r medical reasons, typically injuries. , Also, p...
(Date:11/8/2009)...dicare, improve coverage for all Americans ,, ...RY: Yesterday the United States House of Represen...tion that would strengthen Medicare for seniors an...rices millions of Americans out of affordable heal...r America Act (H.R. 3962) makes prescription drugs...
(Date:11/8/2009)...later, doctors say , , SUNDAY, Nov. 8 (H...e NFL this season, sidelining such stars as quarte..., Officials at the American Podiatric Medical A...s Medicine are warning athletes to take care of th...and lacrosse. , "Many fall sports athletes look...
Breaking Medicine News(10 mins):Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 2Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 3Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 4Health News:Omnetics Connector Corporation Achieves AS9100 Certification 2Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:AARP NY Praises House Passage of Health Care Reform Bill 2Health News:AARP NY Praises House Passage of Health Care Reform Bill 3Health News:AARP NY Praises House Passage of Health Care Reform Bill 4Health News:Rx for Fall Foot Injuries 2
... University of Georgia have conducted a new study ... in the body react to parasitic diseases that affe...ed by scientists at the University of Georgia, tha...ce, states that scientists now have a better under...
...g Parkinson’s patient has challenged the view of T...medical emergency care alarm service, which the// ...inant, Mrs. C, has not minced words that the rulin...ergency care system in her home in 2002. This allo...
...ose brain damage at birth has turned him into a vi...the doctors his parents hold guilty, but that is o... Dispute Redressal (NCDR) forum has ordered the Co...medical negligence. The money was given away last ...
...n and radio ad campaign blaming GOP lawmakers for ...tion drug program has been launched by the// Assoc... The ad campaign accusing the lawmakers for bloc...ican House members from Pennsylvania, Indiana, New...
...00 operations were cancelled by 34 hospitals acros...ing to the report from these hospitals thousands o...the hospitals they were scheduled to be admitted t... these some 3,598 were said to have been cancelled...
...pital has been given a clear idea about the expect...patients in the midst of psychiatric treatments. W...aiting times for patients, Lewis McDonald the depu...State Hospital ensures public safety by providing ...
Other Medicine News:Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 2Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 3Health News:Brain Defect boy Compensated for Medical Error 2Health News:Brain Defect boy Compensated for Medical Error 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2Health News:Cancellations of Operations touch 22,000 2
Snap-In Snap-Out®-II Strong Grasping Forceps Insert
Maryland Dissector, dual-incision
Optima III 45 Noninsulated Maryland Dissector
Palpation Probe, dual-incision
Medicine Products: